Sagimet Biosciences Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $-166.6M | — |
| Jun 2022 | — | $-173.4M | $4.5M |
| Sep 2022 | — | $-180.6M | $2.2M |
| Dec 2022 | — | $-187.0M | $158.0K |
| Mar 2023 | — | $-192.7M | $12.3M |
| Jun 2023 | — | $-198.4M | $18.5M |
| Sep 2023 | — | $97.9M | $101.8M |
| Dec 2023 | — | $91.1M | $75.1M |
| Mar 2024 | — | $190.0M | $176.8M |
| Jun 2024 | — | $183.3M | $96.0M |
| Sep 2024 | — | $170.7M | $77.0M |
| Dec 2024 | — | $155.8M | $75.8M |
| Mar 2025 | — | $139.0M | $64.7M |
| Jun 2025 | — | $130.2M | $42.3M |
| Sep 2025 | — | $119.3M | $32.5M |
| Dec 2025 | — | $111.4M | $35.0M |
| Mar 2026 | — | $102.5M | $36.6M |
| Jun 2026 | — | $256.2M | $165.9M |